上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 论著（临床研究） • 上一篇    下一篇

雄激素受体在乳腺癌中的表达及其预后意义

费晓春 1，徐海燕 2*，闫宁宁 2，徐迎春 3，张凤春 2   

  1. 上海交通大学 医学院 1.附属瑞金医院病理科，上海 200025；2.附属苏州九龙医院肿瘤科，苏州 215021；3.附属仁济医院肿瘤科，上海 200127
  • 出版日期:2017-05-28 发布日期:2017-05-31
  • 作者简介:费晓春（ 1980—），男，主治医师，学士；电子信箱：xcf0222@163.com。徐海燕（1979—），女，副主任医师，硕士生；电子信箱：feelxu2001@163.com。*并列第一作者。
  • 基金资助:

    国家自然科学基金（81301858）；苏州科技计划项目（SYS201308, SYS201404）

Expression of androgen receptor in breast cancer and its prognostic significance

FEI Xiao-chun1, XU Hai-yan2*, YAN Ning-ning 2, XU Ying-chun3, ZHANG Feng-chun2   

  1. 1. Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025; 2. Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021, China; 3. Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
  • Online:2017-05-28 Published:2017-05-31
  • Supported by:

    National Nature Foundation of Science of China, 81301858; Suzhou Science and Technology Program, SYS201308, SYS201404

PDF (PC)

1605

摘要：

目的 ·探讨雄激素受体（AR）在乳腺癌中的表达情况及其预后意义。方法 ·选取2013年10月—2016年12月就诊于上海交通大学医学院附属瑞金医院、仁济医院及苏州九龙医院的183例女性乳腺癌患者，采用免疫组织化学检测肿瘤组织中AR蛋白的表达，分析AR表达与临床病理特征的相关性；采用在线生存分析数据库（Kmplot）观察AR基因的表达与乳腺癌患者预后的相关性。结果 · AR蛋白的阳性率为47.5%。AR阳性者具有相对较低的组织学分级［57.6%（G1/G2）vs 25.0%（G3），P<0.05］。在雌激素受体、孕激素受体及P53阳性者中，AR蛋白的阳性率高于阴性组（P<0.05）。分子分型为管腔型者AR蛋白的阳性率高于表皮生长因子受体-2过表达及三阴性乳腺癌组（51.7% vs 31.6%，P<0.05）。单因素分析结果显示，AR基因阳性的乳腺癌患者的无复发生存、总生存、无远处转移生存明显高于AR阴性者（P<0.05）。结论 ·乳腺癌中AR阳性患者的预后较好，AR通路抑制剂可能成为治疗AR阳性乳腺癌的选择。

关键词: 乳腺肿瘤, 受体, 雄激素, 预后

Abstract:

 Objective · To investigate the expression of androgen receptor (AR) in human breast cancer and its prognostic significance. Methods · A total of 183 female patients with breast cancer were selected. The expression of AR in breast cancer tissues was detected by immunohistochemical staining. The relationship of AR expression with the clinicopathological characteristics was analyzed. Survival analysis of AR gene expression by an online database (Kmplot) was also performed. Results · The positive rate of AR expression was 47.5% and was significantly higher in grade 1 and grade 2 group than that in grade 3 group (57.6% vs 25.0%, P<0.05). Breast cancer patients with estrogen receptor, progesterone receptor and P53 positive expression had significantly increased AR levels (P<0.05). AR expression were significantly higher in patients with luminal type as compared with those in patients with human epidermal growth factor receptor-2 (HER2) positive and patients with triple negative breast cancer (51.7% vs 31.6%，P<0.05). Kaplan-Meier curves identified that AR gene expression was positively correlated with relapse-free survival, overall survival and distant metastasis-free survival of breast cancer patients (P<0.05). Conclusion · The breast cancer patients with AR positive expression have a better prognosis, which suggests that inhibitors of AR pathway may be a treatment option for breast cancer.

Key words: breast neoplasm, receptor, androgen, prognosis